全文获取类型
收费全文 | 39474篇 |
免费 | 3763篇 |
国内免费 | 138篇 |
专业分类
耳鼻咽喉 | 390篇 |
儿科学 | 1275篇 |
妇产科学 | 751篇 |
基础医学 | 5629篇 |
口腔科学 | 545篇 |
临床医学 | 4743篇 |
内科学 | 8531篇 |
皮肤病学 | 1097篇 |
神经病学 | 4046篇 |
特种医学 | 1312篇 |
外国民族医学 | 3篇 |
外科学 | 5473篇 |
综合类 | 330篇 |
一般理论 | 42篇 |
预防医学 | 3475篇 |
眼科学 | 587篇 |
药学 | 2469篇 |
中国医学 | 76篇 |
肿瘤学 | 2601篇 |
出版年
2023年 | 135篇 |
2022年 | 226篇 |
2021年 | 685篇 |
2020年 | 569篇 |
2019年 | 971篇 |
2018年 | 1118篇 |
2017年 | 913篇 |
2016年 | 928篇 |
2015年 | 1137篇 |
2014年 | 1373篇 |
2013年 | 1957篇 |
2012年 | 2326篇 |
2011年 | 2551篇 |
2010年 | 1601篇 |
2009年 | 1479篇 |
2008年 | 2234篇 |
2007年 | 2344篇 |
2006年 | 2251篇 |
2005年 | 2337篇 |
2004年 | 2269篇 |
2003年 | 2238篇 |
2002年 | 2290篇 |
2001年 | 577篇 |
2000年 | 540篇 |
1999年 | 544篇 |
1998年 | 508篇 |
1997年 | 446篇 |
1996年 | 369篇 |
1995年 | 397篇 |
1994年 | 329篇 |
1993年 | 304篇 |
1992年 | 360篇 |
1991年 | 355篇 |
1990年 | 333篇 |
1989年 | 310篇 |
1988年 | 299篇 |
1987年 | 292篇 |
1986年 | 272篇 |
1985年 | 244篇 |
1984年 | 245篇 |
1983年 | 188篇 |
1982年 | 228篇 |
1981年 | 222篇 |
1980年 | 194篇 |
1979年 | 168篇 |
1978年 | 162篇 |
1977年 | 153篇 |
1976年 | 120篇 |
1975年 | 116篇 |
1973年 | 112篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Evelyne Harkemanne Jean‐Louis Dargent Pierre‐Paul Roquet‐Gravy Audrey Bulinckx 《Pediatric dermatology》2019,36(3):365-367
We report a case of benign lymphoplasmacytic plaque (LPP) in a child. These asymptomatic erythematous papulonodular lesions are an emerging clinicopathological entity. Herein, we describe a previously unreported site for LPP lesions, namely, the volar wrist and the distal ipsilateral palm. 相似文献
2.
Jean‐Franois Etter 《Addiction (Abingdon, England)》2019,114(12):2252-2256
3.
4.
5.
Paul J. Devlin Brian W. McCrindle James K. Kirklin Eugene H. Blackstone William M. DeCampli Christopher A. Caldarone Ali Dodge-Khatami Pirooz Eghtesady James M. Meza Peter J. Gruber Kristine J. Guleserian Bahaaladin Alsoufi Linda M. Lambert James E. OBrien Erle H. Austin Jeffrey P. Jacobs Tara Karamlou 《The Journal of thoracic and cardiovascular surgery》2019,157(2):684-695.e8
Objective
Arch obstruction after the Norwood procedure is common and contributes to mortality. We determined the prevalence, associated factors, and practice variability of arch reintervention and assessed whether arch reintervention is associated with mortality.Methods
From 2005 to 2017, 593 neonates in the Congenital Heart Surgeons' Society Critical Left Heart Obstruction cohort underwent a Norwood procedure. Median follow-up was 3.7 years. Multivariable parametric models, including a modulated renewal analysis, were performed.Results
Of the 593 neonates, 146 (25%) underwent 218 reinterventions for arch obstruction after the Norwood procedure: catheter-based (n = 168) or surgical (n = 50) at a median age of 4.3 months (quartile 1-quartile 3, 2.6-5.7). Interdigitation of the distal aortic anastomosis was protective against arch reintervention. Development of ≥ moderate tricuspid valve regurgitation and right ventricular dysfunction at any point was associated with arch reintervention. Nonsignificant variables for arch reintervention included shunt type and preoperative aortic measurements. Surgical arch reintervention was protective against arch reintervention, but transcatheter reintervention was associated with increased reintervention. Arch reintervention was not associated with increased mortality. There was wide institutional variation in incidence of arch reintervention (range, 0-40 reinterventions per 100 years patient follow-up) and in preintervention gradient (range, 0-64 mm Hg).Conclusions
Interdigitation of the distal aortic anastomosis during the Norwood procedure decreased the risk of arch reintervention. Surgical arch reintervention is more definitive than transcatheter. Arch reintervention after the Norwood procedure is not associated with increased mortality. Serial surveillance for arch obstruction, integrated with changes in right ventricular function and tricuspid valve regurgitation, is recommended after the Norwood procedure to improve outcomes. 相似文献6.
7.
PNPLA3 gene polymorphism and response to lifestyle modification in patients with nonalcoholic fatty liver disease 下载免费PDF全文
8.
Dominique Trudel Luminita-Mihaela Avarvarei Michèle Orain Stéphane Turcotte Marie Plante Jean Grégoire Reinhild Kappelhoff David P. Labbé Dimcho Bachvarov Bernard Têtu Christopher M. Overall Isabelle Bairati 《Pathology, research and practice》2019,215(6):152369
Ovarian carcinoma is one of the most lethal malignancies, but only very few prognostic biomarkers are known. The degradome, comprising proteases, protease non-proteolytic homologues and inhibitors, have been involved in the prognosis of many cancer types, including ovarian carcinoma. The prognostic significance of the whole degradome family has not been specifically studied in high-grade serous ovarian cancer. A targeted DNA microarray known as the CLIP-CHIP microarray was used to identify potential prognostic factors in ten high-grade serous ovarian cancer women who had early recurrence (<1.6 years) or late/no recurrence after first line surgery and chemotherapy. In women with early recurrence, we identified seven upregulated genes (TMPRSS4, MASP1/3, SPC18, PSMB1, IGFBP2, CFI – encoding Complement Factor I – and MMP9) and one down-regulated gene (ADAM-10). Using immunohistochemistry, we evaluated the prognostic effect of these 8 candidate genes in an independent cohort of 112 high-grade serous ovarian cancer women. Outcomes were progression, defined according to CA-125 criteria, and death. Multivariate Cox proportional hazard regression models were done to estimate the associations between each protein and each outcome. High ADAM-10 expression (intensity of 2–3) was associated with a lower risk of progression (adjusted hazard ratio (HR): 0.51; 95% confidence interval (CI): 0.29-0.87). High complement factor I expression (intensity 2–3) was associated with a higher risk of progression (adjusted HR: 2.30, 95% CI: 1.17–4.53) and death (adjusted HR: 3.42; 95% CI: 1.72–6.79). Overall, we identified the prognostic value of two proteases, ADAM-10 and complement factor I, for high-grade serous ovarian cancer which could have clinical significance. 相似文献
9.
Erika Cecon Anna Ivanova Marine Luka Florence Gbahou Anne Friederich Jean‐Luc Guillaume Patrick Keller Klaus Knoch Raise Ahmad Philippe Delagrange Michele Solimena Ralf Jockers 《Journal of pineal research》2019,66(2)
Melatonin receptors play important roles in the regulation of circadian and seasonal rhythms, sleep, retinal functions, the immune system, depression, and type 2 diabetes development. Melatonin receptors are approved drug targets for insomnia, non‐24‐hour sleep‐wake disorders, and major depressive disorders. In mammals, two melatonin receptors (MTRs) exist, MT1 and MT2, belonging to the G protein‐coupled receptor (GPCR) superfamily. Similar to most other GPCRs, reliable antibodies recognizing melatonin receptors proved to be difficult to obtain. Here, we describe the development of the first monoclonal antibodies (mABs) for mouse MT1 and MT2. Purified antibodies were extensively characterized for specific reactivity with mouse, rat, and human MT1 and MT2 by Western blot, immunoprecipitation, immunofluorescence, and proximity ligation assay. Several mABs were specific for either mouse MT1 or MT2. None of the mABs cross‐reacted with rat MTRs, and some were able to react with human MTRs. The specificity of the selected mABs was validated by immunofluorescence microscopy in three established locations (retina, suprachiasmatic nuclei, pituitary gland) for MTR expression in mice using MTR‐KO mice as control. MT2 expression was not detected in mouse insulinoma MIN6 cells or pancreatic beta‐cells. Collectively, we report the first monoclonal antibodies recognizing recombinant and native mouse melatonin receptors that will be valuable tools for future studies. 相似文献
10.